Core Viewpoint - Tempest Therapeutics, Inc. is exploring a range of strategic alternatives to advance its clinical programs and maximize stockholder value, including potential mergers, acquisitions, partnerships, and licensing arrangements [1][2]. Company Overview - Tempest Therapeutics is a clinical-stage biotechnology company focused on developing targeted and immune-mediated therapeutics for cancer treatment [7]. - The company is headquartered in Brisbane, California, and has a diverse portfolio of small molecule product candidates [7]. Strategic Alternatives - The company has engaged MTS Health Partners, L.P. to assist in evaluating strategic alternatives [1]. - No specific timeline has been set for the evaluation process, and no agreements for transactions have been reached yet [2]. Clinical Programs - Amezalpat (TPST-1120) is ready for Phase 3 trials, having received Orphan Drug and Fast Track designations from the FDA for hepatocellular carcinoma (HCC) [3][4]. - TPST-1495 is set to enter a Phase 2 trial for familial adenomatous polyposis (FAP) in 2025, with FDA clearance obtained [6][9]. Recent Developments - Amezalpat has shown a six-month improvement in median overall survival when combined with atezolizumab and bevacizumab compared to the standard of care [4][5]. - Positive feedback from the FDA was received regarding the pivotal Phase 3 trial for amezalpat in combination with existing therapies for HCC [4]. Future Outlook - The company believes there is significant commercial potential in its pipeline, particularly with the positive data from ongoing clinical trials [2].